2019
Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.
Metzger Filho O, Stover D, Asad S, Ansell P, Watson M, Loibl S, Geyer C, O'Shaughnessy J, Untch M, Rugo H, Huober J, Golshan M, Sikov W, Von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Symmans W. Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study. Journal Of Clinical Oncology 2019, 37: 510-510. DOI: 10.1200/jco.2019.37.15_suppl.510.Peer-Reviewed Original ResearchPathologic complete responseNAC regimensNeoadjuvant chemotherapyPhase III studyT cell infiltrationClinico-pathologic variablesSignificant predictorsIII studyImmune signaturesComplete responseIndependent predictorsResearch biopsiesTNBC subtypesTotal macrophagesM2 macrophagesMultivariate analysisTNBCTumor proliferationImmunophenotypeTumorsBasal-likeRegimensChemotherapyCIBERSORTPAM50
2009
Factors affecting surgical decision-making in patients undergoing BRCA1/2 testing at breast cancer diagnosis.
Stadler Z, Stoeckert K, Perez A, Regan M, Golshan M, Garber J. Factors affecting surgical decision-making in patients undergoing BRCA1/2 testing at breast cancer diagnosis. Cancer Research 2009, 69: 1095. DOI: 10.1158/0008-5472.sabcs-1095.Peer-Reviewed Original ResearchBilateral mastectomyFamily cancer historyPre-test probabilityBC patientsBRCA1/2 mutationsBreast MRIBreast conservationIndependent predictorsSurgical treatmentCancer historyBC diagnosisBreast cancerEarly-stage breast cancerDana-Farber Cancer InstituteLogistic regressionPositive genetic test resultAbnormal MRI resultsDeleterious BRCA1/2 mutationsAbnormal MRI findingsDefinitive surgical treatmentBRCA1/2 germline mutationsTest-negative patientsTime of diagnosisStage breast cancerStrong independent predictor